Progress and potential of immune checkpoint blockade for treating advanced renal cell carcinoma

被引：0

作者：

Tykodi, Scott S. ^{[1
,2
]}

机构：

[1] Univ Washington, Dept Med, Div Med Oncol, Seattle, WA 98109 USA

[2] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA

来源：

IMMUNOTHERAPY | 2013年 / 5卷 / 06期

关键词：

CTLA-4; antigen; immune checkpoint; immunotherapy; LAG-3; PD-1; receptor; PD-L1; renal cell carcinoma; T lymphocyte; HIGH-DOSE INTERLEUKIN-2; INTERFERON-ALPHA; DOUBLE-BLIND; RECOMBINANT INTERLEUKIN-2; METASTATIC MELANOMA; T-CELLS; PHASE-I; CANCER; TRIAL; REGRESSION;

D O I：

10.2217/IMT.13.39

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Adaptive immune responses appear to influence the natural history of cancer progression, as well as therapeutic outcomes, in cancer patients. However, accumulating evidence suggests resistance mechanisms exploited by tumors may play a dominant role in limiting the effectiveness of T cell-mediated cancer therapies. Inhibitory coreceptors expressed by T lymphocytes, or so-called immune checkpoints, are now recognized to play critical roles in regulating the termination of adaptive immune responses. An overview of early-phase trial results distinguish blocking antibodies targeting inhibitory coreceptors as a highly promising approach to cancer immunotherapy for patients with advanced clear cell renal cell carcinoma. Prospects for advanced-phase clinical testing and novel therapy combinations with immune checkpoint blocking agents are discussed.

引用

页码：607 / 619

页数：13

共 66 条

[1] Vaccination of Metastatic Renal Cancer Patients with MVA-5T4: A Randomized, Double-Blind, Placebo-Controlled Phase III Study [J].

Amato, Robert J. ;

Hawkins, Robert E. ;

Kaufman, Howard L. ;

Thompson, John A. ;

Tomczak, Piotr ;

Szczylik, Cezary ;

McDonald, Mike ;

Eastty, Sarah ;

Shingler, William H. ;

de Belin, Jackie ;

Goonewardena, Madusha ;

Naylor, Stuart ;

Harrop, Richard .

CLINICAL CANCER RESEARCH, 2010, 16 (22) :5539-5547

[2] Biomarkers for Immunostimulatory Monoclonal Antibodies in Combination Strategies for Melanoma and Other Tumor Types [J].

Ascierto, Paolo A. ;

Kalos, Michael ;

Schaer, David A. ;

Callahan, Margaret K. ;

Wolchok, Jedd D. .

CLINICAL CANCER RESEARCH, 2013, 19 (05) :1009-1020

[3] Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4 [J].

Beck, Kimberly E. ;

Blansfield, Joseph A. ;

Tran, Khoi Q. ;

Feldman, Andrew L. ;

Hughes, Marybeth S. ;

Royal, Richard E. ;

Kammula, Udai S. ;

Topalian, Suzanne L. ;

Sherry, Richard M. ;

Kleiner, David ;

Quezado, Martha ;

Lowy, Israel ;

Yellin, Michael ;

Rosenberg, Steven A. ;

Yang, James C. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (15) :2283-2289

[4] Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer [J].

Brahmer, Julie R. ;

Tykodi, Scott S. ;

Chow, Laura Q. M. ;

Hwu, Wen-Jen ;

Topalian, Suzanne L. ;

Hwu, Patrick ;

Drake, Charles G. ;

Camacho, Luis H. ;

Kauh, John ;

Odunsi, Kunle ;

Pitot, Henry C. ;

Hamid, Omid ;

Bhatia, Shailender ;

Martins, Renato ;

Eaton, Keith ;

Chen, Shuming ;

Salay, Theresa M. ;

Alaparthy, Suresh ;

Grosso, Joseph F. ;

Korman, Alan J. ;

Parker, Susan M. ;

Agrawal, Shruti ;

Goldberg, Stacie M. ;

Pardoll, Drew M. ;

Gupta, Ashok ;

Wigginton, Jon M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26) :2455-2465

[5] Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates [J].

Brahmer, Julie R. ;

Drake, Charles G. ;

Wollner, Ira ;

Powderly, John D. ;

Picus, Joel ;

Sharfman, William H. ;

Stankevich, Elizabeth ;

Pons, Alice ;

Salay, Theresa M. ;

McMiller, Tracee L. ;

Gilson, Marta M. ;

Wang, Changyu ;

Selby, Mark ;

Taube, Janis M. ;

Anders, Robert ;

Chen, Lieping ;

Korman, Alan J. ;

Pardoll, Drew M. ;

Lowy, Israel ;

Topalian, Suzanne L. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (19) :3167-3175

[6] A Phase I Pharmacokinetic and Biological Correlative Study of IMP321, a Novel MHC Class II Agonist, in Patients with Advanced Renal Cell Carcinoma [J].

Brignone, Chrystelle ;

Escudier, Bernard ;

Grygar, Caroline ;

Marcu, Manon ;

Triebel, Frederic .

CLINICAL CANCER RESEARCH, 2009, 15 (19) :6225-6231

[7] Soluble human LAG-3 molecule amplifies the in vitro generation of type 1 tumor-specific immunity [J].

Casati, C ;

Camisaschi, C ;

Rini, F ;

Arienti, F ;

Rivoltini, L ;

Triebel, F ;

Parmiani, G ;

Castelli, C .

CANCER RESEARCH, 2006, 66 (08) :4450-4460

[8]

COPPIN C, 2005, COCHRANE DB SYST REV, V3

[9] T Lymphocytes infiltrating various tumour types express the MHC class II ligand lymphocyte activation gene-3 (LAG-3):: role of LAG-3/MHC class II interactions in cell-cell contacts [J].

Demeure, CE ;

Wolfers, J ;

Martin-Garcia, N ;

Gaulard, P ;

Triebel, F .

EUROPEAN JOURNAL OF CANCER, 2001, 37 (13) :1709-1718

[10] Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade [J].

Downey, Stephanie G. ;

Klapper, Jacob A. ;

Smith, Franz O. ;

Yang, James C. ;

Sherry, Richard M. ;

Royal, Richard E. ;

Kammula, Udai S. ;

Hughes, Marybeth S. ;

Allen, Tamika E. ;

Levy, Catherine L. ;

Yellin, Michael ;

Nich, Geoffrey ;

White, Donald E. ;

Steinberg, Seth M. ;

Rosenberg, Steven A. .

CLINICAL CANCER RESEARCH, 2007, 13 (22) :6681-6688

← 1 2 3 4 5 6 7 →